To Lower Or Not? EV Pricing Dilemma Hampers Ford’s Profitability, Warns Analyst

This could pose a significant challenge for automakers like Ford Motor Company (NYSE: F) in achieving profitability in the EV sector.

Global Autos Analyst Tom Narayan expressed concerns over the decreasing prices of electric vehicles (EVs), which could potentially hinder profitability for automakers.

What Happened: Narayan, during CNBC’s “Last Call” on Wednesday, pointed out that the pricing for EVs seems to be on a downward trend. This could pose a significant challenge for automakers like Ford Motor Company (NYSE:F) in achieving profitability in the EV sector.

He stated, “If pricing keeps coming down it’ll be tough to get there.”

See Also: Tesla Q1 Earnings Preview: Is EV Giant No Longer A ‘Growth Stock?’ Analysts Cautious, Want Answers About Robotaxis, Model 2

Why It Matters: Narayan’s tweet comes in the wake of Ford’s CFO, John Lawler, expressing concerns over the rapid decrease in revenue due to EV price cuts. Lawler emphasized the company’s commitment to cost-cutting in its EV segment to counter the losses.

Earlier, Tesla Inc. (NASDAQ:TSLA) had also announced significant price cuts in all trim levels of its electric vehicles in China, following a round of price cuts in the U.S.

Stellantis NV (NYSE:STLA) CEO Carlos Tavares had previously cautioned against price reductions that might risk profitability and potentially make car manufacturers acquisition targets.

Price Action: As of close on Wednesday, Ford shares closed at $13.26, Tesla at $160.55, and Stellantis at $24.95, according to Benzinga Pro.

Read Next: Elon Musk Reacts As ARK Invest Analyst Says ‘It’s Going To Be Very Hard’ For Tesla Rivals ‘To Catch Up To  Them’ In Pricing: ‘Accurate’

Image via Shutterstock


Engineered by Benzinga Neuro, Edited by
Pooja Rajkumari


The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you.
Learn more.


Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Evusheld Long-acting Antibody Combination Recommended for Approval in the EU for the Treatment of COVID-19

AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

AZN